Hypothalamic obesity caused by craniopharyngioma surgery
Conditions
Interventions
Test Group:Conventional treatment regimen + semaglutide therapy
Control group:Conventional treatment options
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 48 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosis was: craniopharyngioma surgery, obesity (BMI>=28 kg/m^2); (2) Age: 18-45 years old; (3) Conventional diet and exercise treatment were ineffective for 6 months; (4) normal liver and kidney function (ALT and AST< = 3 * upper limit of normal range); (5) Regular drug treatment, no tumor recurrence; (6) Voluntarily participate and sign the informed consent form. If the above criteria are met, the drug can be used
Exclusion criteria
Exclusion criteria: (1)Use of GLP-1 receptor agonists (e.g., liraglutide, benaglutide, exenatide, dulaglutide) or prescription weight-loss medications (e.g., orlistat, fenfluramine) within the 3 months prior to participation in this study. (2)History of other tumors, medullary thyroid carcinoma (MTC), acute or chronic pancreatitis, significant cardiovascular history, liver or kidney impairment, infectious diseases, gastrointestinal motility disorders or obstructive diseases, and psychiatric disorders. (3)Pregnant or breastfeeding women. (4)Patients or family members unable to comprehend the conditions and objectives of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight; | — |
Secondary
| Measure | Time frame |
|---|---|
| Height;Waist circumference;Blood glucose;Fasting insulin;Glycated hemoglobin (HbA1c);IGF-1; | — |
Countries
China
Contacts
Public ContactJiangfeng Mao
Peking Union Medical College Hospital
Outcome results
None listed